X0306 4 2023-01-26 0 0001814114 Orchestra BioMed Holdings, Inc. OBIO 0001418239 Smith Geoffrey Wade C/O ORCHESTRA BIOMED HOLDINGS, INC. 150 UNION SQUARE DRIVE NEW HOPE PA 18938 1 0 0 0 Common Stock 2023-01-26 4 A 0 3488 A 3488 D Common Stock 2023-01-26 4 A 0 201319 A 201319 I By Ascent Biomedical Ventures II NY, LP Common Stock 2023-01-26 4 A 0 1049224 A 1049224 I By Ascent Biomedical Ventures II, LP Common Stock 2023-01-26 4 A 0 256623 A 256623 I By Ascent Biomedical Ventures Synecor, LP Warrants (Right to Buy) 11.50 2028-01-26 Common Stock 15000 15000 D Warrants (Right to Buy) 21.5054 2023-01-26 4 A 0 43940 A 2023-05-31 Common Stock 43940 43940 I By Ascent Biomedical Ventures II NY, LP Warrants (Right to Buy) 21.5054 2023-01-26 4 A 0 136097 A 2023-05-31 Common Stock 136097 136097 I By Ascent Biomedical Ventures II, LP Warrants (Right to Buy) 21.5054 2023-01-26 4 A 0 519 A 2023-05-31 Common Stock 519 519 I By Ascent Biomedical Ventures Synecor, LP Stock Options (Right to Buy) 4.3011 2023-01-26 4 A 0 18600 A 2028-08-07 Common Stock 18600 18600 D Stock Options (Right to Buy) 4.3011 2023-01-26 4 A 0 6975 A 2029-08-06 Common Stock 6975 6975 D Stock Options (Right to Buy) 10.00 2023-01-26 4 A 0 23250 A 2032-08-25 Common Stock 23250 23250 D Represents restricted stock awards ("RSAs") that vest in two equal annual installments beginning on April 12, 2023, subject to the reporting person's continued service with Orchestra BioMed Holdings, Inc. ("New Orchestra") on such vesting date. Received in connection with the business combination of Orchestra BioMed, Inc. ("Orchestra") with Health Sciences Acquisitions Corporation 2 (the "Business Combination") in exchange for 1,621 RSAs of Orchestra. Received in exchange for shares of Orchestra common stock that automatically converted into shares of New Orchestra common stock on a 1 for 0.465 basis upon the closing date of the Business Combination. The Reporting Person is a managing member of ABV, LLC, which serves as general partner to Ascent Biomedical Ventures II NY, LP, Ascent Biomedical Ventures II, LP and Ascent Biomedical Ventures Synecor, LP. The Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of his pecuniary interest, if any, therein. Fifty percent (50%) of these warrants will become exercisable 24 months after completion of the business combination and the remaining fifty percent (50%) of these warrants will become exercisable 36 months after completion of the business combination, in each case subject to the reporting person's continued service with New Orchestra or one of its subsidiaries through such date. The warrants are immediately exercisable in full. Received in connection with the Business Combination in exchange for warrants to acquire 94,494 shares of Orchestra common stock for $10.00 per share. Received in connection with the Business Combination in exchange for warrants to acquire 292,682 shares of Orchestra common stock for $10.00 per share. Received in connection with the Business Combination in exchange for warrants to acquire 1,117 shares of Orchestra common stock for $10.00 per share. The stock option is fully vested and exercisable. Received in connection with the Business Combination in exchange for options to acquire 40,000 shares of Orchestra common stock for $2.00 per share. Received in connection with the Business Combination in exchange for options to acquire 15,000 shares of Orchestra common stock for $2.00 per share. The stock option vests in quarterly installments with a one year cliff beginning on August 18, 2023. Received in connection with the Business Combination in exchange for options to acquire 50,000 shares of Orchestra common stock for $4.65 per share. /s/ Todd Finger, Attorney-in-Fact 2023-01-30